Clinical trials: Widespread Chronic Pain
Mast Cell Activation Syndrome, Mast Cell Activation Disorder Idiopathic
Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
This study will determine if FSD201 reduces the average daily 24-hour recall pain intensity after 28 and 56 days of treatment in adults with chronic widespread musculoskeletal nociplastic pain.
- Trial name
- NCT05652907
- Testing
- FSD201
- Where
- 3 sites in United States, Canada
- Volunteers
- 2 people
- Sponsor
- Quantum Biopharma
Chronic Widespread Pain, Fibromyalgia
Efficacy and Safety of IGN-ES001 in Chronic Widespread Pain With or Without Fibromyalgia
This is a randomized, double-blind, placebo-controlled exploratory trial to investigate efficacy and safety of food supplement IGN-ES001 in patients with chronic widespread pain (CWP) with or without fibromyalgia (FM).
- Trial name
- NCT03058224
- Testing
- IGN-ES001, Parol 500 mg Tablets (acetaminophen)
- Where
- 23 sites in Turkey (Türkiye)
- Volunteers
- 230 people
- Sponsor
- IgNova GmbH
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc